Human medicines European public assessment report (EPAR): Triumeq, abacavir,dolutegravir,lamivudine, Date of authorisation: 31/08/2014, Revision: 36, Status: Authorised

Submitted by Anonymous (not verified) on 4 September 2025 - 10:24

Human medicines European public assessment report (EPAR): Triumeq, abacavir,dolutegravir,lamivudine, Date of authorisation: 31/08/2014, Revision: 36, Status: Authorised

Orphan designation: palmitoyl-conjugated tricyclo-DNA antisense oligonucleotide 5'-Palm-C6-*GGA GAT GgC AGT TTC-3 Treatment of Duchenne muscular dystrophy, 18/07/2025 Positive

Submitted by Anonymous (not verified) on 4 September 2025 - 9:36

Orphan designation: palmitoyl-conjugated tricyclo-DNA antisense oligonucleotide 5'-Palm-C6-*GGA GAT GgC AGT TTC-3 Treatment of Duchenne muscular dystrophy, 18/07/2025 Positive

Orphan designation: human bispecific monoclonal antibody targeting ALK1 and BMPRII Treatment of hereditary haemorrhagic telangiectasia, 18/07/2025 Positive

Submitted by Anonymous (not verified) on 4 September 2025 - 9:30

Orphan designation: human bispecific monoclonal antibody targeting ALK1 and BMPRII Treatment of hereditary haemorrhagic telangiectasia, 18/07/2025 Positive

Orphan designation: adeno-associated viral vector serotype 9 containing the human CTNNB1 gene Treatment of autosomal dominant polycystic kidney disease, 18/07/2025 Positive

Submitted by Anonymous (not verified) on 4 September 2025 - 9:28

Orphan designation: adeno-associated viral vector serotype 9 containing the human CTNNB1 gene Treatment of autosomal dominant polycystic kidney disease, 18/07/2025 Positive

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More